CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SpringWorks Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SpringWorks Therapeutics Inc
100 Washington Blvd
Phone: (203) 883-9490p:203 883-9490 STAMFORD, CT  06902-9302  United States Ticker: SWTXSWTX
Business Summary
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Daniel S.Lynch 65 8/1/2019 8/1/2017
Chief Executive Officer, Director SaqibIslam 54 8/1/2018 8/1/2018
Chief Financial Officer FrancisPerier 64 8/1/2019 8/1/2019
10 additional Officers and Directors records available in full report.

Business Names
Business Name
SpringWorks Subsidiary 1, Inc.
SpringWorks Subsidiary 2, Inc.
SpringWorks Subsidiary 3, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 305 (As of 12/31/2023)
Outstanding Shares: 74,386,403 (As of 11/5/2024)
Shareholders: 93
Stock Exchange: NASD
Federal Tax Id: 834066827
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024